Therapy for the treatment of non-hodgkin lymphoma

TW202631146APending Publication Date: 2026-08-01CELGENE CORP +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-11-04
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001071037_001
    Figure TWG2TA001071037_001
  • Figure TWG2TA001071037_002
    Figure TWG2TA001071037_002
  • Figure TWG2TA001071037_003
    Figure TWG2TA001071037_003
Patent Text Reader

Abstract

Provided herein are methods of treating and / or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (“Compound A, A-S, or A-R”), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.
Need to check novelty before this filing date? Find Prior Art